Top ▲

Cutaneous T cell lymphoma

Disease ID:1229
Name:Cutaneous T cell lymphoma
Associated with:0 target
2 immuno-relevant ligands
CTCL | cutaneous T-cell lymphoma
A type of non-Hodgkin's lymphoma, primarily presenting in skin lesions.
Database Links
Disease Ontology: DOID:0060061


No target related data available for Cutaneous T cell lymphoma


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
denileukin diftitox
Immuno Disease Comments: Approved drug for CTCL.
Clinical Use: Denileukin diftitox is used to destroy malignant leukemia and lymphoma cells which express cell surface IL-2 receptors. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed molecular target, in this case the IL-2R, to substantiate its MMOA, and have therefore not tagged a primary drug target. | View biological activity
Immuno Disease Comments: Approved drug for two subtypes of cutaneous lymphoma: mycosis fungoides or Sézary syndrome- FDA 2018.
Clinical Use: Approved first in Japan, for the treatment of relapsed or refractory adult T cell leukemia/lymphoma. The 2018 EMA and FDA approvals allow Poteligeo® to be used as a treatment for two rare cutaneous T cell lymphomas; relapsed or refractory mycosis fungoides or Sézary syndrome (following at least one prior systemic therapy). In Europe the drug has EMA orphan designation for the treatment of cutaneous and peripheral T cell lymphomas. | View clinical data
Bioactivity Comments: Peptide sequence analysis of the heavy chain variable region of mogamulizumab matches sequence ID 9 from patent US7504104 [1], linking this antibody with clones Gal1LV1, Gal1LV2 or Gal1LV3. A graph of CCR4 binding by these antibody clones is provided in the patent, but no affinity value is specified. | View biological activity


Show »

1. Shitara K, Nakamura K, Hosaka E, Tanaka A, Koike M. (2009) Monoclonal antibodies which preferentially bind to chemokine receptors, used for immunotherapy, as antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system disorders or antiallergens. Patent number: US7504104. Assignee: Kyowa Hakko Kogyo Co., Ltd. Priority date: 31/08/2001. Publication date: 17/01/2010.